Formulation: A crystalline solid
Formal Name: 7,8-dihydro-8-oxo-7-(2-propen-1-yl)-guanosine
Purity: ≥98%
Formula Markup: C13H17N5O6
Formula Weight: 339,3
Shelf life (days): 1460
CAS Number: 121288-39-9
Notes: Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7).{42514,42515} It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.{42515}. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively).{42514} Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs).{42516} Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.{42517}
English
Deutsch
